Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
| ▸ | IGF1R | P08069 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.32 |
| ▸ | MAOA | P21397 | 2/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9928221 | 0.89 | MEN1 (0.32) | MEN1POLBKMT2A | |
| SCHEMBL9943139 | 0.85 | MEN1 (0.32) | MEN1POLBKMT2A | |
| SCHEMBL1009516 | 0.84 | PGR (0.32) | MEN1POLBKMT2ACA12CA1 | |
| SCHEMBL29664129 | 0.84 | PGR (0.32) | MEN1POLBKMT2ACA12CA1 | |
| SCHEMBL9928246 | 0.83 | EDNRB (0.32) | — | |
| SCHEMBL1046559 | 0.83 | MEN1 (0.32) | MEN1KMT2AKDM4EALDH1A1LMNA | |
| SCHEMBL29453311 | 0.83 | MEN1 (0.32) | MEN1KMT2AKDM4EALDH1A1LMNA | |
| SCHEMBL25604639 | 0.82 | MAOA (0.33) | MEN1POLBKMT2AMAOAKDM4E | |
| SCHEMBL29664183 | 0.82 | PGR (0.34) | MEN1POLBKMT2AKDM4EALDH1A1 | |
| SCHEMBL1680041 | 0.82 | PGR (0.34) | MEN1POLBKMT2AKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120145974-A1 | CHROMENE COMPOUND | TOKUYAMA CORPORATION (JP) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120145974-A1 | CHROMENE COMPOUND | CRY2, CYP2J2, NR0B2 | MEN1 2833/4885POLB 2967/4885KMT2A 1418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.